Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?

Investors rotated into perceived 'safer' healthcare and retail names, lifting Moderna ~70% and Target >20% year-to-date amid geopolitical (Iran) and U.S. growth concerns that cooled demand for AI plays. Moderna reaffirmed guidance for up to 10% revenue growth this year as it pivots to seasonal vaccines, oncology and rare-disease programs; the piece suggests waiting for a dip after the rapid rally. Target’s multi-year turnaround under new CEO Michael Fiddelke (including a $2B investment this year) has driven shares higher; the stock trades at ~14x forward earnings versus peers >40x, implying potential upside if execution continues.

Analysis

The recent rotation into healthcare and staples is less a vote of confidence in those business models than a liquidity-driven de-risking: large, concentrated flows into ‘safe’ names compress idiosyncratic volatility in those sectors while amplifying dispersion in high-growth tech. That creates two exploitable market microstructures — lower implied vols in defensives (cheaper protection) and fatter skew in growth names (expensive downside insurance) that will persist so long as macro uncertainty remains elevated.

For biotech, the practical second-order constraint is manufacturing and regulatory binary timing, not just clinical merit. If seasonal vaccine franchises scale, CDMO capacity, fill/finish slots, and lipid nanoparticle suppliers become the margin lever; delays or capacity bottlenecks will move revenue curves by quarters, not days, and will produce outsized price action around approval windows.

In retail, a multi-year store-refresh and assortment pivot is an earnings-and-cash-flow story that plays out over quarters; the stock-level re-rating requires sustained comps improvement and margin recovery, and it invites competitive responses (price matching, loyalty investment) that can compress sector margins. Wage and freight cost trajectories remain the key macro levers — one sustained tick higher and the recovery narrative gets considerably harder to prove.

Immediate risks that could reverse trends are: a macro shock (growth slowdown, CPI resurgence) that sends risk assets back to long-duration discounting within weeks; geopolitical spikes that reroute flows into cyclical/defense plays; and biotech regulatory setbacks that turn optimism into a durable multiple contraction. Use option expiries and upcoming regulatory/earnings windows as time-bound catalysts for sizing and hedging.

Key Decisions for Investors

• Long TGT (size 1–2% NAV): accumulate on pullbacks of 5–10% over the next 3 months. Horizon 6–12 months; target asymmetric return 20–35% if comps and margin inflect. Hard stop if same-store sales miss by >200bps or relative underperformance vs peer median >10% in 60 days.
• Long MRNA via a defined-risk options structure (size 0.75–1% NAV): buy a 6–9 month call spread (ATM to ~20–30% OTM) rather than naked calls to limit premium loss. Catalyst window = upcoming regulatory readouts and seasonal commercialization cadence; payoff target 2.5x premium on positive readouts, max loss = premium paid.
• Relative-value pair: long TGT / short COST (equal notional, size 0.5–1% NAV each) — horizon 6–12 months. Thesis: re-rating from execution at TGT vs multiple tailwind risk at the multiple-rich peer. Exit or trim if spread fails to compress after two consecutive quarters of positive comps or if TGT misses execution targets.
• Near-term protection: buy short-dated (30–90 day) puts on high-beta tech (e.g., NVDA) or purchase VIX call protection (size 0.5–1% NAV) to hedge a fast rotation back into risk-off driven by macro or geopolitical shocks. Treat as insurance — cost accepted as pay-for-convexity; trim on realized vol spikes >60% intraday.